Pachner AR - Search Results

1

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.

Pachner AR, Warth JD, Pace A, Goelz S; INSIGHT investigators. Pachner AR, et al. Neurology. 2009 Nov 3;73(18):1493-500. doi: 10.1212/WNL.0b013e3181bf98db. Neurology. 2009. PMID: 19884577 Clinical Trial.

2

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.

Pachner AR, Cadavid D, Wolansky L, Skurnick J. Pachner AR, et al. Neurology. 2009 Nov 3;73(18):1485-92. doi: 10.1212/WNL.0b013e3181bf9919. Neurology. 2009. PMID: 19884576 Clinical Trial.

3

An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients.

Pachner AR. Pachner AR. Neurology. 2003 Nov 25;61(10):1444-6. doi: 10.1212/01.wnl.0000094198.37489.11. Neurology. 2003. PMID: 14638976

4

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Polman CH, et al. Among authors: pachner ar. Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4. Lancet Neurol. 2010. PMID: 20610349

5

Measurement of antibodies to interferon beta in patients with multiple sclerosis.

Pachner AR. Pachner AR. Arch Neurol. 2001 Aug;58(8):1299-300. doi: 10.1001/archneur.58.8.1299. Arch Neurol. 2001. PMID: 11493174 No abstract available.

6

Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients.

Pachner AR, Narayan K, Pak E. Pachner AR, et al. Neurology. 2006 Feb 14;66(3):444-6. doi: 10.1212/01.wnl.0000196467.71646.72. Neurology. 2006. PMID: 16476953

7

Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

Pachner AR, Bertolotto A, Deisenhammer F. Pachner AR, et al. Neurology. 2003 Nov 11;61(9 Suppl 5):S24-6. doi: 10.1212/01.wnl.0000092361.04511.d0. Neurology. 2003. PMID: 14610107 Review.

8

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.

Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD. Cadavid D, et al. Among authors: pachner ar. Neurology. 2009 Jun 9;72(23):1976-83. doi: 10.1212/01.wnl.0000345970.73354.17. Epub 2009 Mar 11. Neurology. 2009. PMID: 19279320 Clinical Trial.

9

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

Pachner AR, Dail D, Pak E, Narayan K. Pachner AR, et al. J Neuroimmunol. 2005 Sep;166(1-2):180-8. doi: 10.1016/j.jneuroim.2005.06.003. J Neuroimmunol. 2005. PMID: 16005084

10

The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta.

Pachner AR, Oger J, Palace J. Pachner AR, et al. Neurology. 2003 Nov 11;61(9 Suppl 5):S18-20. doi: 10.1212/01.wnl.0000092359.93813.92. Neurology. 2003. PMID: 14610105 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

129 results

Search Page